Moderna, Inc. (NASDAQ:MRNA) said it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers’ 2026 Top Employers Survey. The recognition marks the company’s twelfth consecutive year in the survey’s top-employer results.
The survey recognised Moderna in areas including its corporate image, leadership and direction, and workplace culture. The company said the assessment reflected its reputation for innovation and research quality, its focus on continuous improvement, and a collaborative, data-driven working environment.
Stéphane Bancel, Moderna’s Chief Executive Officer, attributed the recognition to the people who have built and developed the company. He said Moderna’s work was united by a focus on advancing mRNA science and translating that work into advances for patients.
Science has surveyed its readership for more than 20 years to identify the top 20 pharmaceutical and biotechnology companies regarded as leading employers. The 2026 findings drew on approximately 5,100 completed surveys from Science readers and other invited participants.
Respondents were primarily based in North America, which accounted for 71% of participants. Europe represented 19%, while Asia/Pacific Rim accounted for 6%.
Moderna said it received approval for its fourth and fifth products in 2026. mCOMBRIAX® received marketing authorisation in the European Union in April 2026 for preventing influenza disease and COVID-19 caused by SARS-CoV-2.
mFLUSIVA®, a vaccine for seasonal influenza, was approved by the U.S. Food and Drug Administration in August 2026.
Also in August 2026, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial. The study evaluated intismeran autogene, an investigational individualised mRNA cancer therapy, alongside KEYTRUDA® in patients with resected stage IIB-IV melanoma.
Tracey Franklin, Moderna’s Chief People and Digital Technology Officer, said the company was combining employee expertise with digital capabilities and AI to address complex problems in new ways and create a greater impact for patients.
Moderna also said it marked the fourth anniversary of the Moderna Charitable Foundation and published its fifth annual Impacting Human Health Report as part of its social responsibility activities.
Moderna describes its business as focused on mRNA medicine. The company said its mRNA platform supports the development of therapeutics and vaccines across infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.
Moderna announced that it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey. The company said this was the twelfth consecutive year it had received the recognition.
Moderna was recognised for its corporate image, leadership and direction, and work culture. The company said the recognition reflected its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.
Moderna said it had been recognised as a top employer by Science for twelve consecutive years.
The ranking was conducted through Science and Science Careers' 2026 Top Employers Survey. Science has surveyed its readership for more than 20 years to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers.
The 2026 survey's findings were based on approximately 5,100 completed surveys from readers of Science and other survey invitees.
A vast majority of survey participants came from North America, Europe and Asia/Pacific Rim. The source gives the regional shares as 71% from North America, 19% from Europe and 6% from Asia/Pacific Rim.
Stéphane Bancel, Moderna's Chief Executive Officer, said the recognition was a testament to the thousands of people who had helped build and evolve the company. He also said Moderna believed the best science happened when talented people were given the opportunity to tackle important problems and make an impact.
Tracey Franklin, Moderna's Chief People and Digital Technology Officer, said the company was building an organisation that brought together its people's expertise with digital capabilities and AI. She said this was intended to solve complex problems in new ways and create a greater impact for patients.
Moderna said it received approval for its fourth and fifth products in 2026. mCOMBRIAX® received marketing authorisation in the European Union in April 2026 for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2, while mFLUSIVA® was approved by the U.S. Food and Drug Administration in August 2026 for seasonal influenza.
In August 2026, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial. The trial evaluated intismeran autogene, an investigational individualised mRNA cancer therapy, in combination with KEYTRUDA® in patients with resected stage IIB-IV melanoma.
Moderna said it marked the fourth anniversary of the Moderna Charitable Foundation and issued its fifth annual Impacting Human Health Report as part of its ongoing commitment to social responsibility.
Moderna describes itself as a leader in the creation of the field of mRNA medicine. It said its mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.
The source identifies Moderna, Inc. as trading on NASDAQ under the ticker symbol NASDAQ:MRNA.